Plasma endothelin in postmenopausal women with type 2 diabetes mellitus and metabolic syndrome: A comparison of oral combined and transdermal oestrogen-only replacement therapy

Diabetes, Obesity and Metabolism

Volumn 2, Issue 5, 2000, Pages 293-298

  Saltevo, J ^a   Puolakka, J ^a   Ylikorkala, O ^b   Quon, Michael J ^c  

^a Central Hospital of Middle Finland   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Angiotensin convertase enzyme inhibitors; Endothelin; Hormonal replacement therapy; Metabolic syndrome; Postmenopausal; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DRUG FORMULATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SYNDROME; VASOCONSTRICTION;

EID: 0034525159     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00087.x     Document Type: Article

References (34)

1. Vessel wall interactions regulating thrombosis
2. Mechanism of disease: Endothelins
3. Regulatory functions of the vasculator endothelium
4. Diabetes and atherosclerosis: An epidemiologic view
5. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
6. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
7. Banting Lecture 1988: Role of insulin resistance in human disease
8. Insulin resistance, a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease
9. Hyperinsulinemia and clustering of cardiovascular risk factors in middle-aged hypertensive Finnish men and women
10. Insulin resistance and lipoprotein metabolism
11. Hyperglycemia and microvascular disease in diabetes
12. Endothelial dysfunction: Cause of the insulin resistance syndrome
13. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes
14. Role of plasma and urinary andothelin-1 in early diabetic and hypertensive nephropathy
15. Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities
16. Postmenopausal hormonal replacement decreases plasma levels of Endothelin-1
17. The effect of oestrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women
18. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin and thromboxane
19. Endothelin levels decrease after oral and nonoral oestrogen in postmenopausal women with increased cardiovascular risk factors
20. Plasma endothelin-1 levels in hypertension and chronic renal failure
21. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
22. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
23. Sex hormones and lipoprotein metabolism
24. Effects of oestrogen or oestrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Oestrogen/Progestin Interventions (PEPI) Trial
25. Pharmacokinetics and pharmacodynamics of transdermal dosage form of 17 oestradiol: Comparison with conventional oral oestrogens used for hormone replacement
26. Postmenopausal oestrogen and progestin use and the risk of cardiovascular disease
27. Postmenopausal hormone therapy and mortality
28. Cardiovascular and cancer morbidity and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)
29. Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
30. Endothelin inhibition as a biologic target for treating hypertension
31. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus
32. ACE inhibitors improve endothelial function in type-1 diabetic patients with normal arterial pressure and microalbuminuria
33. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: A randomized double-blind study